Josephina P. M. Vrouwe

Josephina P. M. Vrouwe

Auto-generated profile, based on publicly available information

Josephina P. M. Vrouwe

Centre for Human Drug Research, Leiden, the Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2021 in Osteoarthritis and Cartilage Open
Verified
Journal Article
Open access
JVJ.P.M. Vrouwe
J.P.M. Vrouwe
JBJacobus (Koos) Burggraaf
Jacobus (Koos) Burggraaf
MKM. Kloppenburg
M. Kloppenburg
FSF.E. Stuurman
F.E. Stuurman
Osteoarthritis (OA) is the most common cause of disability in older adults, and leads to a huge unmet medical need, as no registered disease modifying OA drugs (DMOADs), but only symptomatic treatments, are available. New targets and compounds for these targets, are currently under investigation. The objective of this paper is to provide an overview of compounds under investigation for OA in phase II and III. We performed a review of OA trials for pharmacological interventions registered on the National Library of Medicine ClinicalTrials.gov website with a completion date in 2017 or later. The database search yielded 255 results, of which 184 studies were included in this review. These were structured in compounds targeting pain, immunomodulators, stem cell therapy, platelet rich plasma and DMOADs with cartilage and/or bone resorption modifying properties. The results provide an overview of the fields in development and may include future treatment options for OA, by which a registered DMOADs may become more than a utopic vista. Further knowledge on pathophysiology and new approaches of value-based drug development could be an opportunity for the optimization of drug development in OA.

20 August 2021 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
JVJosephina P. M. Vrouwe
Josephina P. M. Vrouwe
IKIngrid Kamerling
Ingrid Kamerling
MEMichiel J. van Esdonk
Michiel J. van Esdonk
JMJosbert M. Metselaar
Josbert M. Metselaar
FSFrederik E. Stuurman
Frederik E. Stuurman
SOSusanne Osanto
Susanne Osanto
Dexamethasone has antitumor activity in metastatic castration resistant prostate cancer (mCRPC). We aimed to investigate intravenous liposome‐encapsulated dexamethasone disodium phosphate (liposomal dexamethasone) administration in mCRPC patients.In this exploratory first‐in‐man study, patients in part A received a starting dose of 10 mg followed by five doses of 20 mg liposomal dexamethasone at 2‐week intervals. Upon review of part A safety, patients in part B received 10 weekly doses of 18.5 mg. Primary outcomes were safety and pharmacokinetic profile, secondary outcome was antitumor efficacy.Nine mCRPC patients (5 part A, 4 part B) were enrolled. All patients experienced grade 1–2 toxicity, one (part B) patient experienced grade 3 toxicity (permanent bladder catheter‐related urosepsis). No infusion‐related adverse events occurred. One patient had upsloping glucose levels ≤9.1 mmol/L. Trough plasma concentrations of liposomal‐ and free dexamethasone were below the lower limit of quantification (LLOQ) in part A, and above LLOQ in three patients in part B (t1/2 ~50 h for liposomal dexamethasone), trough concentrations of liposomal‐ and free dexamethasone increased toward the end of the study. In seven of nine patients (78%) patients, stable disease was observed in bone and/or CT scans at follow‐up, and in one (part B) of these seven patients a >50% PSA biochemical response was observed.Bi‐ and once weekly administrations of IV liposomal dexamethasone were well‐tolerated. Weekly dosing enabled trough concentrations of liposomal‐ and free dexamethasone >LLOQ. The data presented support further clinical investigation in well‐powered studies.Clinical trial registration: ISRCTN 10011715.

18 August 2022 in BJUI Compass
Verified
Journal Article
Open access
JVJosephina P. M. Vrouwe
Josephina P. M. Vrouwe
PHPauline M. L. Hennus
Pauline M. L. Hennus
NHNeveen A. T. Hamdy
Neveen A. T. Hamdy
SOSusanne Osanto
Susanne Osanto
PWPeter-Paul Willemse
Peter-Paul Willemse
Context: Testicular germ cell tumour (TGCT) survivors are potentially at risk of developing osteoporosis, because of increased risk for disturbed bone remodelling associated with hypogonadism and anti‐cancer treatment. A number of studies show bone loss and increased fracture risk in TGCT survivors, but data are scarce. There are no clinical guidelines or recommendations issued to address skeletal health in this group of patients potentially at high risk for osteoporosis.Objective: To conduct a systematic review of available literature addressing bone health in TGCT patients. Subgroup analysis was performed to identify risk factors for bone loss and increased fracture risk.Evidence Acquisition: Relevant databases, including MEDLINE, Embase and the Cochrane Library, including all English written comparative studies addressing bone health in TGCT patients, were searched up to December 2021 and a narrative synthesis was undertaken. Risk of bias (RoB) was assessed using Cochrane ROBINS‐I tool.Evidence Synthesis: Ten studies (eight cross‐sectional and two longitudinal), recruiting a total of 1997 unique TGCT patients, were identified and included in the analysis. Bone health was reported in various ways in different studies, and subgroups were defined heterogeneously, resulting in a widely varying prevalence of osteoporosis of up to 73.2% of patients. Six studies reported low BMD associated with higher luteinizing hormone levels and one study showed a correlation between follow up duration and bone loss.Conclusions: TGCT survivors are at risk of developing osteoporosis and sustaining fragility fractures. Chemotherapy, pituitary‐gonadal axis dysfunction and ageing are key risk factors, although available data are scarce. With increasing survival of TGCT patients, a clear unmet need has been identified to systematically evaluate and monitor skeletal health in larger numbers of survivors in order to develop best clinical practice guidelines to manage the insidious but potentially preventable and treatable skeletal complications of TGCT.

18 September 2026 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
ACAnouk Carmen
Anouk Carmen
JVJosephina P.M. Vrouwe
Josephina P.M. Vrouwe
FSFranziska Saxer
Franziska Saxer
IKIna Kramer
Ina Kramer
AMAngelika Meyer
Angelika Meyer
MSMatthias Schieker
Matthias Schieker
No disease-modifying drugs are approved for osteoarthritis (OA), a prevalent and debilitating chronic condition. Based on preclinical data, LRX712 was envi